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Abstract
Background: Testing for KRAS mutations in metastatic colorectal cancer (mCRC) on formalin-fixed, paraffin
embedded (FFPE) tumor tissue has become standard of care. Different molecular methods exist to determine
hotspot KRAS mutations in exon 2, 3 and 4, but testing is often limited by the sensitivity and the speed of analysis.
The aim of this retrospective study was to establish the clinical performance of the Idylla™ KRAS Mutation Test on
FFPE tumor samples of patients with mCRC.
Methods: KRAS mutation analysis was performed using the therascreen KRAS on the RotorGene Q platform (CE-IVD;
Qiagen) and results were subsequently compared to the Idylla™ KRAS Mutation Test. Discordant result testing was
performed with massive parallel sequencing or alternative routine approaches.
Results: Data from 182 samples were used to show that the overall agreement between the two methods for
mutation characterization was 96.7% [95%CI: 93.0%-98.5%]. Six out of 182 samples (3.3%) showed true discordant
results.
Conclusion: The Idylla™ KRAS Mutation Test allows for a fast and reliable analysis of FFPE samples with a
turnaround-time of two hours without the need of molecular infrastructure or expertise in order to guide the
personalized treatment of colorectal cancer patients.
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Background
Colorectal cancer (CRC) is the fourth most common cause
worldwide of cancer and counts for approximately 10% of
cancer related mortalities in western countries [1, 2].
Treatment options for metastatic CRC include targeted
therapies with monoclonal antibodies (mAbs), namely
cetuximab (Erbitux, Merk KgaA, Darmstadt, Germany)
and panitumumab (Vectibix, Amgen Thousand Oaks, CA,
United States) [3]. These molecules both target the extra-
cellular domain of the epidermal growth factor receptor
(EGFR) protein and compete with ligands, leading to the
blocking of ligand induced intracellular signal transmission.
Both cetuximab and panitumumab have been shown to
improve survival in mCRC patients, both as monotherapy
as well as in combination with conventional chemother-
apies [4–7]. However, mCRC patients whose tumors
harbor mutations in the rat sarcoma viral oncogene homo-
log (RAS) gene family, including the kirsten RAS (KRAS)
and neuroblastoma RAS (NRAS) proto-oncogenes, do not
benefit from therapy with these mAbs [6, 8, 9].
This is due to the constitutive activation of the mutated
proteins, independently of ligand binding. As a conse-
quence, testing of the RAS mutation status in mCRC pa-
tients functions as predictive marker to guide therapy
with anti EGFR-antibodies [10–12].
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Based on the pooled analysis of the RAS status of over
3000 patients, the overall prevalence of RAS mutations
was calculated as being 55.9%, with the majority of these
mutations being present in KRAS exon 2 (42.6%). Muta-
tions in KRAS exon 3 (3.8%), KRAS exon 4 (6.2%) and
NRAS exon 2 (2.9%), NRAS exon 3 (4.2%) and NRAS
exon 4 (0.3%) were shown to be less prevent, but still
account for over 15% of all RAS mutations in the mCRC
setting [13]. Hence, extended RAS testing of tumor
tissue (primary or metastatic) beyond KRAS exon 2 is
now recommended both by the European Society of
Medical Oncology (ESMO) and by the National
Comprehensive Cancer Network (NCCN) [3, 6, 8].
Various molecular techniques exist to detect KRAS
mutations, each with their advantages and disadvantages
such as differences in cost, test duration, sensitivity,
specificity, reproducibility, capacity to quantify the mu-
tated alleles and ability to detect new mutations [14–16].
Only two methods currently available to test for KRAS
mutations in FFPE samples are approved by the Food
and Drug Administration, namely the therascreen KRAS
RGQ PCR Kit (Qiagen Manchester Ltd, Manchester, UK)
and the cobas® KRAS Mutation Test (Roche, Branchburg,
NJ, USA) [17]. Briefly, both methods require tissue depar-
affinization, extraction of genomic DNA from formalin-
fixed, paraffin-embedded (FFPE) tissue, DNA quantitation
and followed by quantitative polymerase-chain reaction
(qPCR) on specific instruments. Extensive data-analysis is
not required. The therascreen KRAS RGQ PCR Kit allows
the detection of seven mutations in codons 12 and 13,
while the cobas® KRAS Mutation Test additionally detects
mutations in codon 61. This latter method however does
not allow full characterization of the individual muta-
tions. Both methods are equally labor-intensive and
require a turnaround-time of 3-4 h. Also, both tech-
niques preferentially use pooling of several samples in
view of the optimal use of the kit, often leading to a
more prolonged turnaround-time.
The Idylla™ KRAS Mutation Test (Biocartis, Mechelen,
Belgium) is CE-IVD labeled and allows characterization
of 21 hot-spot KRAS mutations in exons 2, 3 and 4,
namely G12D, G12A, G12C, G13D, G12V, G12S, G12R,
A59T/E/G, Q61H, Q61K, Q61R/L, K117N and A146P/
T/V. Furthermore, this test does not require separate
deparaffinization, DNA quantification and genomic
DNA isolation, since all reactions for deparaffinization,
DNA extraction and PCR are fully automated and per-
formed in a single-use cartridge. This study aimed at
comparing the clinical performance of the Idylla™ KRAS
Mutation Test to the therascreen KRAS RGQ PCR Kit
for 182 valid results obtained from mCRC FFPE samples.
Comparison includes the overall percentage agreement,
percent positive agreement and percent negative agree-
ment, defined as percentages of valid Idylla™ results in
agreement with or different from the comparator




This study was approved by the Ethical committee of
the University Hospital Antwerp (UZA) and includes
FFPE tumor samples from 230 patients with mCRC that
were referred for KRAS mutation analysis at our institute
(UZA) between 2010 and 2015. Additionally, 22 com-
mercial samples were provided by Biocartis to UZA,
bringing the total number of samples to 252.
Of these samples, 104 (41.3%) had been collected less
than 1 year before testing, 53 (21.0%) between 1 and
2 years, 45 (17.86%) between 2 and 3 years, 36 (14.3%)
between 3 and 4 years and 14 (5.6%) between 4 and
5 years. Older samples could not be tested due to restric-
tions imposed by the institutional review board.
The study was conducted at UZA where the Idylla™ as
well as the therascreen KRAS RGQ PCR reference test
were performed. From the 252 eligible FFPE samples ana-
lyzed, 77 (30.56%) were metastatic tissue samples and 171
samples (67.86%) were derived from the primary tumor.
For four samples, the tumor origin was unknown.
Based on histological assessment of H&E staining,
consecutive slides of the samples were enriched by man-
ual macrodissection to reach a tumor content of at least
25%. These samples were subsequently tested with the
Idylla™ KRAS Mutation Test (IUO) or with the reference
test. The influence of necrotic tissue on the results was
evaluated.
Mutation detection by the Idylla™ molecular diagnostic
system
Ready-to-use Idylla™ KRAS Mutation Test cartridges
(IUO), allowing the detection of mutations in codons 12,
13, 59, 61, 117 and 146 of the KRAS gene, were used
(G12D, G12A, G12C, G12V, G12S, G12R, G13D, A59T/
E/G, Q61H/Q61H, Q61K/Q61K, Q61R/L, K117N/
K117N and A146P/T/V) were provided by the company
(Biocartis, Mechelen, Belgium). These cartridges contain
the necessary reagents to perform sample preparation,
real-time PCR amplification and detection, starting from
insertion of FFPE tissue into the cartridge. Briefly, the
process steps in the test are the FFPE liquefaction and
cell lysis followed by real-time PCR using allele specific
primers. Amplification of a KRAS sequence in intron4/
exon5, serving as a sample processing control, is in-
cluded in each run. The presence of a mutant genotype
is determined by calculating the difference between the
KRAS Sample Processing Control Cq and the Cq ob-
tained for the KRAS mutant signal(s). In case of multiple
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mutations, only the dominantly detected mutation (low-
est ΔCq value) is currently reported.
Idylla™ analyses were performed according to the man-
ufacturer’s recommendations for investigational use.
Briefly, a tumor area of at least 50 mm2 (for 5 μm slices)
per sample was transferred into the cartridges. The time
between preparation of the slide(s) and the actual testing
should not exceed 60 days. A tumor tissue content of at
least 25% was obtained, if needed after macrodissection,
allowing the detection of mutations present with an al-
lelic frequency between 1% for G12R and ~15% for
A146V/T/P in this investigational phase of the assay.
The performance characteristics of the CE-IVD Idylla™
KRAS Mutation Test have been extended in the mean-
time for mutations with a low prevalence, meaning that
all mutations down to an allele frequency of 5% were
shown to be detectable. This implies that the instruc-
tions for use state a 10% tumor tissue content (TTC)
requirement from July 2016 on. Repeat testing was per-
formed once, whenever an invalid KRAS result was ob-
tained. Invalid results may be caused by a variety of
reasons including presence of inhibitors in the sample,
insufficient amplifiable DNA present in the sample, in-
correct placement of a sample in a cartridge, or sample
volume out or range. In addition, incorrectly stored car-
tridges, cartridges used that exceeded their in-use period
after removal from the pouch, or cartridge malfunction-
ing were reported as possible reasons for invalid results.
Limit of detection
The Limit of Detection (LOD) is defined as the lowest
KRAS mutation copy number consistently detected in ≥
95% of the cases (with 95% confidence) at an allelic fre-
quency of 5%.
Four clinical KRAS mutation positive FFPE specimens
with 5-10% tumor cell content were included to verify
the LOD. Specimens with a previously determined
G12D, G12V and G12C mutation could be collected.
Mutation detection using the therascreen RGQ PCR KRAS Kit
After deparaffinization with xylene, genomic DNA from
mCRC samples was manually extracted from 5 μm slides
using the QIAamp DNA FFPE Tissue Kit according to the
manufacturer’s recommendation. Samples with a tumor
content of at least 20% were used with a total minimal
tumor area of 4 mm2, using one or more consecutive sec-
tions. Total amplifiable DNA was first assessed using
qPCR using an internal control per sample. Samples with
Cq values between 21.92 and 32.00 were considered as
valid and suitable for subsequent KRAS analysis. In the
event DNA was too concentrated (Cq < 21.92), the sample
was diluted and re-tested. Samples with a Cq > 32 were
excluded from further analysis. KRAS mutation analysis
was then performed for valid samples in 8 different PCR
reactions: 7 mutation reactions and 1 control reaction.
The PCR run and data analysis were performed according
to manufacturer’s instructions. Repeat testing was per-
formed once, whenever an invalid KRAS result was
obtained. Invalid KRAS results are due to failure of in-
ternal, negative or positive controls as stated by the
manufacturer.
Discordant testing
Targeted sequencing of discordant samples was per-
formed using the SOMATIC1 MASTR v2 Kit (Multipli-
com; Niel, BE). This kit specifically amplifies full coding
regions of KRAS, NRAS and BRAF with short amplicons
(168-255 bp). Since characterization of variants in the
full coding region of the BRAF gene is not required, only
a single-plex PCR was performed amplifying full exons
of KRAS and NRAS and only exon 15 of BRAF, as speci-
fied by the manufacturer. Briefly, DNA quality of sam-
ples was first assessed using the QC plex, according to
the instructions for use. Only samples with a DQC of >
0.12 were considered suitable for further analysis. Samples
were subsequently amplified using 2-5 μl DNA (8-20 ng).
The library quantification was carried out using the Qubit
DNA HS Kit (Life Technologies). For sequencing on the
MiSeq Illumina platform, the 600v3 sequencing reagent
kit was used. Data analysis was performed with SeqNext
v.4.2.1 (JSI Medical Systems, Ettenheim, Germany). Ana-
lysis was performed for samples reaching the 1000x cover-
age at the genomic positions of the hotspot mutations
covered by the Idylla™ and therascreen tests.
Alternatively, Sanger sequencing was used whenever
MPS was not successful in mutation detection. First,
PCR was performed using the following primers: 5’-
GTAAAACGACGGCCAGGTGTGACATGTTCTAATA
TAG-3’ (Forward) and 5’- TTGGATCATATTCGTC
CACAA-3’ (Reverse) for KRAS exon 2, 5’- GTAAAAC
GACGGCCAGCCAGACTGTGTTTCTCCCTTCTCAG
G -3’ (Forward) and 5’- AGAAAGCCCTCCCCAGT
CCTCA-3’ (Reverse) for KRAS exon 3, 5’- GTAAA
ACGACGGCCAGTCAGATCTGTATTTATTTCAGTG
TTACTTACCT-3’ (Forward) and 5’- CAGGAAACA
GCTATGACCGACTCTGAAGATGTACCTATGGTCC
TA-3’ (Reverse) for KRAS exon 4 (K117N) and 5’-GT
AAAACGACGGCCAGTAATGACATAACAGTTATGA
TTTTGCAGAAAA-3’ (Forward) and 5’-CAGGAAACA
GCTATGACCCAGGCTCAGGACTTAGCAAGAAG-3’
(Reverse) for KRAS exon 4 (A146/VT/P). In this reac-
tion, after an initial denaturation step at 95 °C during
120 s, the PCR mixture was subjected to 45 rounds of
amplification consisting of a 30 s denaturation at 94 °C, a
30 s annealing at 64 °C and a 30 s elongation at 72 °C.
Sanger sequencing was performed using a universal M13
tag (5’-GTAAAACGACGGCCAG-3’) on an ABI3130
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Instrument. Analysis was performed with SeqPatient soft-
ware (JSI Medical Systems, Ettenheim, Germany).
Diagnostic performance calculations
Overall agreement (% total agreement), negative and posi-
tive agreement was estimated together with a 95% two-
sided confidence interval based on Wilson’s score method
[18] at the dichotomous level, “mutation detected” versus
“no mutation detected”. Percentage overall agreement is
defined as the proportion of concordant results against
the sum of concordant and discordant results.
Positive agreement is defined as the proportion of
valid tests resulting in the detection of the mutation that
are in concordance between the Idylla™ system and the
comparator method against the number of all mutations
detected by the comparator system.
Negative agreement is defined as the proportion of
concordant tests without the mutation against the num-
ber of all comparator tests without mutation.
The statistical comparison of invalid Idylla™ KRAS
Mutation Test Results for each sample collection time
interval was performed with the Chi squared test [19].
Results
Study population and overall performance of the Idylla™
system
The Idylla™ system is a quick, on-demand system that
allows fast analysis of hot spot KRAS mutations in exon
2, 3 and 4 starting from 50 mm2 tissue sections with
minimum 25% tumor content in order to reach an LOD
ranging between 1% ~ 15% depending on the mutation.
Macrodissection was performed in 97 samples (38.5%).
There was no significant difference in percentage invalid
results between macro- and non-macro-dissected sam-
ples. Eight samples with a 1-10% tumor content could
not be macro-dissected, eg. due to small tissue size or
spread-out tumor cells, and were tested as such. In 2 out
of these samples, a KRAS mutation was detected, which
was also true for the therascreen comparator test. Also,
30 out of 31 samples not reaching the 50 mm2 cut-off
tumor tissue area yielded a successful result.
It was not always possible to maintain the maximum
delay of 60 days between the date of sectioning and the
Idylla™ KRAS Mutation Test due to the large amount of
samples tested. Overall, 60 samples (23.8%) were tested
within 60 days and 192 samples (76.2%) after 60 days.
There was no correlation between the number of invalid
results and the overdue time (data not shown).
We investigated the possibility that a statistically sig-
nificant association was present between the age of the
samples, defined as the time between the collection and
testing date, namely <1 year, 1–2 years, 2–3 years, 3–4
years, 4–5 years, and the number of invalid results.
Overall, 7 samples turned out to be invalid, amongst
which 1 sample was part of category < 1 year and 6 sam-
ples belonged to the category 4–5 years. A statistical dif-
ference was noted (p < 0.05) between this last category
and all other categories.
In addition, the potential effect of necrotic tissue on
the results was evaluated. The number of valid results
did not correlate with a necrotic category, namely <10%,
11-25%, 26-50% (data not shown).
Verification of the limit of detection of the IdyllaTM KRAS
Mutation Test
The LOD of the Idylla™ KRAS Mutation Test was veri-
fied using clinical FFPE samples containing a low TTC
(5–10%) and harboring a previously determined KRAS
mutation. Results are shown in Table 1. The percentage
agreement was 100%.
Comparison of KRAS specifications
The percentage overall agreement of KRAS mutation
analysis took into account that the number of KRAS mu-
tations detected by the therascreen and Idylla™ method is
not completely equal. More specifically, both methods
detect identical mutations in exon 2, but the Idylla™ plat-
form additionally detects hotspot mutations in exon 3
and 4. Since the therascreen kit is the only FDA ap-
proved KRAS mutation analysis platform allowing com-
parison at the mutation-specific level, this was the
comparator method of choice.
KRAS mutation analysis using the therascreen reference
method
The therascreen KRAS RGQ kit first required a quality
check by qPCR to determine eligibility for subsequent
KRAS analysis. Out of the 252 samples that fulfilled the
criteria of the kit, 227 samples generated a QC result
within the acceptable Cq range (90.1%). Only these 227
samples were further tested for KRAS mutation analysis
and a valid result was subsequently generated for 195
samples. Thirty two samples had a non-reportable invalid
result, due to test or system alerts. Hence, the overall suc-
cess rate was 77.4% (195/252) with 86% valid results (195/
227) and 14% invalid results (32/227). Overall, KRAS mu-
tations in exon 2 were detected in 83 samples (42.6%).
Table 1 Verification of LOD with clinical samples
MPS Idylla™ KRAS Mutation Test
16S106 G12C (10% TTC: 31%VAF) G12C
16K11 G12C (5-10% TTC: 33% VAF) G12C
16O1048 G12V (10% TTC; 3% VAF) G12V
16EM117 G12D (10% TTC, 18%VAF) G12D
TTC tumor tissue content, VAF variant allele frequency
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Comparison therascreen versus Idylla™ KRAS Mutation
Test at dichotomous Mutation Detected level
There were 252 eligible samples of which 195 and 245
generated a valid result with therascreen or Idylla™, re-
spectively. Overall, 194 samples generated a valid result
with both methods. Since the therascreen KRAS test
only detects 7 out of the 21 mutations detected by the
Idylla™ KRAS Mutations Test, discordant results are ob-
tained whenever one of the 14 other mutations (A59E,
A59G, A59T, Q61K, Q61K, Q61L, Q61R, Q61H, Q61H,
K117N, K117N, A146P, A146T, A146V) was detected by
the Idylla™ KRAS Mutation Test. In this study there
were 13 discordant-by-design mutations detected by
Idylla™, of which one had an invalid result with therasc-
reen. This means that overall there were 12 mutations
discordant by design amongst the valid samples, which
were not further taken into account for statistical ana-
lyses. Table 2 shows the raw data used to calculate the
agreement between both methods at the dichotomous
level ‘mutation detected’ versus ‘no mutation detected’.
The overall agreement for 182 samples was 96.7% with a
lower limit of the 95% confidence interval (CI) of 93.0%.
Positive agreement was calculated to be 98.8% with a
lower limit of the 95% CI of 93.2%, while the negative
agreement was calculated to be 95.1% with a lower limit
of the 95% CI to be 89.0%. Finally, the KAPPA statistic
of 93.3% indicated almost perfect agreement.
Comparison between therascreen and Idylla™ results at
the mutation-specific level
The details for the different mutation-specific types as
detected by Idylla™ and therascreen at the mutation-
specific level are shown in Table 3.
From this Table 3, it is clear that two mutant-mutant
discordant results were detected, meaning that both
methods detected a mutation, but the mutation was dif-
ferently genotyped: two samples were diagnosed with a
G12V and G13D mutation using Idylla, but therascreen
detected this in both cases as a 12SER mutation. Fur-
thermore, 13 samples contained a mutation that could
not be detected by the therascreen assay since they were
present in exon 3 and 4. These samples are therefore
discordant-by-design specimens, and were subsequently
excluded from agreement calculations. Within these 13
samples, two mutant-mutant discordants were found
that are however concordant in respect to the dichotom-
ous result ‘mutation detected’ or ‘no mutation detected’
(italic and bold in Table 3).
Discordant testing
Overall, 6 true discordant results were noted, indicated
in with an asterisk (*) in Table 3 and summarized in
Table 4.
One mutation detected by the comparator method
was missed by Idylla™, and 5 mutations detected by
Idylla™ were not detected by the comparator method.
These discordant samples were further investigated. The
method of choice to perform the analysis of these dis-
cordant samples was the SOMATIC 1 KRAS/NRAS/
BRAF kit (Multiplicom). This kit allows parallel detec-
tion of mutations in all exons of KRAS, NRAS and exon
15 of BRAF using massive parallel sequencing (MPS).
MPS was chosen since it allows an analysis at low vari-
ant allele frequency (VAF), comparable to what can be
achieved with Idylla™ and therascreen. It was preferred
to use freshly isolated genomic DNA starting from FFPE
slides, but due to limitations of the available material, a
new extraction could only be done for 5 out of the 6
samples (Table 4). However, massive parallel sequencing
was performed for all 6 samples. A first step with the
chosen MPS method requires a Quality Control check of
the extracted DNA. Only One (1) sample fulfilled the
criteria, namely Sample S8322. Targeted sequencing con-
firmed the G12V mutation as detected with the Idylla™
platform. The VAF of this mutation, which weakly corre-
lates with the tumor content in the sample, was 37%.
MPS was not successful in confirmatory testing in five
out of six cases. For these cases, conventional Sanger
sequencing was used as the method of choice. For all
five cases, the result obtained with the comparator
method could be confirmed. All five samples had a
tumor tissue content of over 15%, suggesting that results
were not hampered by a lack of analytical sensitivity of
this approach.
Confirmatory testing of exon 3 or 4 Idylla results
Whenever one of the 14 mutations in KRAS exon 3 or 4
(A59E, A59G, A59T, Q61K, Q61K, Q61L, Q61R, Q61H,
Q61H, K117N, K117N, A146P, A146T, A146V) was de-
tected by the Idylla™ KRAS Mutation Test, they could
not be verified by design with the therascreen KRAS
RGQ kit. Although the 13 samples, showing one of these
mutations (Table 3: italic), were not taken into account
for agreement calculations, it was considered interesting
to confirm the presence of the mutation by investigating
them with routine reference approaches, namely MPS or
Sanger Sequencing. Furthermore, the 2 mutant-mutant
Table 2 Agreement table at the dichotomous level for valid,
non-missing results
mCRC samples (n = 182) therascreen KRAS RGQ PCR Kit
Idylla™ KRAS Mutation Test KRAS mutation KRAS Wild-type Totals
KRAS Mutation 79 5 84
KRAS Wild-type 1 97 98
Totals 80 102 182
Overall agreement between therascreen and Idylla™ platform for detection of
KRAS mutations. mCRC metastatic colorectal cancer. KRAS Wild type = no
mutation detected
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discordants (Samples S8494 and S8546 in Table 5) were
investigated as well. The results of these 15 samples are
summarized in Table 5.
From Table 5, one can understand that out of the 13
samples that yielded as successful result, 11 samples had
a mutation specific concordant result to the Idylla™
result. For 3 samples (S8250, S8431, S8546), a discordant
result was obtained between the Idylla™ KRAS Mutation
Test and the reference approach: one sample (S8431)
was identified as KRAS wild-type and two samples
(S8250 and S8546) were discordant at the mutation-
specific level, but concordant with Idylla™ at the dichot-
omous ‘mutation detected’ level.
Discussion
Testing for presence of hotspot mutations in exons 2, 3
and 4 of the KRAS gene has become standard of care in
the mCRC setting [3]. Several clinical trials indicate that
patients with tumors wild-type for KRAS benefit from
anti-EGFR antibody therapy [20]. Two methods are cur-
rently FDA approved and could therefore be considered
as the current gold standard for testing in FFPE material,
namely the therascreen KRAS RGQ PCR Kit (Qiagen)
and the cobas® KRAS Mutation Test (Roche) [17]. These
methods are however hampered by the fact that they
only detect and identify mutations in exon 2 or that they
do not discriminate between mutations at the amino
acid level for exon 2 or 3, respectively. In addition, both
methods require pooling of samples for optimal kit
usage and require tissue deparaffination, DNA quantita-
tion and manual isolation of genomic DNA [17]. This
retrospective study compared the therascreen RGQ
KRAS Mutation Kit to the Idylla™ KRAS Mutation Test.
This latter platform allows detection of 21 KRAS muta-
tions in hotspot amino acids of exon 2, 3 and 4 using
simultaneous DNA extraction and qPCR reaction in a
single-use cartridge, directly on FFPE, with a result
within 2 h.
Several parameters were evaluated, such as the per-
centage necrotic tissue in relation to the number of valid
Idylla™ KRAS results, as well as small tissue area and the
overdue age of the samples, defined as the number of
days between sectioning and testing. For these 3 param-
eters no correlation could be found, indicating that the
Table 3 Agreement table at the mutation specific level
Idylla™ G12A G12C G12D G12R G12S G12V G13D No mutation
detected
Invalid A59E/P/V Q61H/H2 Q61K/K2 Q61L/R K117N1/N2 A146T/V/0 Total
therascreen
12ALA 6 1a 7
12CYS 6 1 7
12ASP 25 25
12ARG 3 3
12SER 6 1 1 8




1a 1a 3a 97 1 3 2 4 112
Invalid/Run
Control failed
2 1 3 2 1 41 6 1 57
Total 6 8 26 4 9 19 21 139 7 1 3 0 0 3 6 252
Genotyping concordance between the Idylla™ test and the reference test. Italic: discordant by design specimens. a True discordant samples. Bold: mutant-mutant
discordant results
Table 4 True discordant results at the dichotomous level “mutation detected” versus “no mutation detected” for mutations in exon 2
Sample ID Idylla™ therascreen Confirmatory testing New DNA extraction?
S8251 No mutation detected 12ALA No mutation detected Yes
S8261 G13D No mutation detected No mutation detected Yes
S8320 G12R No mutation detected No mutation detected No
S8322 G12V No mutation detected G12V Yes
S8382 G13D No mutation detected No mutation detected Yes
S8505 G13D No mutation detected No mutation detected Yes
Listing of the samples with a true discordant result, namely mutated versus not mutated KRAS. Confirmatory testing of mutational status of the samples are
shown in column 3
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Idylla™ KRAS Mutation test is a robust assay, overcom-
ing less optimal sample conditions (data not shown).
Moreover, out of the 31 samples that did not reach the
cut-off of 50 mm2, a valid result could be obtained in 30
cases. This result suggests that the test might be more
sensitive than stated for small tumor areas. We further
investigated the impact of the sample collection date on
the number of invalid results and a significant association
was found between samples older than 4 years (n = 14)
and the number of invalid results (n = 6) (p < 0.05). Pre-
analytical conditions of the samples, such as time of
fixation, were highly controlled in the lab, suggesting the
invalid results are a result of the storage of the FFPE
blocks influencing the DNA integrity and hence its ampli-
fication in PCR reactions as was previously demonstrated
[21]. The impact of even older archived samples on KRAS
mutation analysis could not be assessed due to ethical
limitations imposed by the ethical committee. The clinical
importance of these findings is however expected to be of
lesser importance, since KRAS biomarker determination
is most likely to be requested within 4–5 years after
sample collection.
Comparison of the Idylla™ platform with the therascreen
assay was performed for 252 samples, generating 194 valid
results overall with both methods. There were respectively
57 and 7 invalid or failed results with therascreen and
Idylla™, respectively. Of note, the samples that turned out
to be invalid with the Idylla™ platform were all but one
also invalid using therascreen. The success rate of the
Idylla™ platform is therefore 97.2% and is hence consid-
ered acceptable within the scope of this study. Of note,
the success rate of therascreen was only a disappointing
77.4% due to invalid calls (n = 33) and test failures after
QC (n = 24). It is difficult to explain this lower success
rate, but a possible explanation might lie in tissue loss dur-
ing the DNA extraction process. Since manual DNA
extraction is a separate step in the DNA extraction
process, it seems possible that tissue got lost, eg. during
tissue scraping/collection or column purification, a step
which is not required with Idylla™. Of note, 16 samples
had a tissue surface area of less than 25 mm2 on HE, all of
which were invalid after QC step using therascreen. One
can imagine that even a small loss of tissue might hamper
the subsequent DNA steps. No further explanation
could be found, not in the number of used slides nor in
the technician performing the test or the age of the
samples. Such performance would hamper the labora-
tory workflow efficiency.
Since the diagnostic yield of the Idylla™ platform is
higher compared to therascreen due to the inclusion of
exon 3 and 4 mutations, agreement at the dichotomous
level ‘mutation detected’ versus ‘mutation not detected’
could only be performed for 182 out of 194 results. The
overall agreement between both methods was 96.7%
[95% CI: 93.0%-98.5%], with corrected kappa statistics of
0.93 (Table 2), indicating that both methods almost per-
fectly agree. For 6 samples, agreement was not obtained
and further investigation was warranted. First, in order
to avoid any bias, we performed a new genomic DNA
isolation whenever sufficient material was available. Sec-
ond, using MPS or Sanger sequencing we could confirm
for two samples the result as detected by the Idylla™
platform and for four samples the results as obtained
with therascreen (Table 4). Of note, the confirmation of
Table 5 Confirmatory testing using routine reference approaches
Sample ID Idylla™ Therascreen Confirmatory result Reference approach VAF (%)
S8470 A146P/T/V N/A A146T MPS 31
S8476 A146P/T/V N/A A146T MPS 20
S8342 A146P/T/V N/A A146V MPS 2
S9195 A146P/T/V N/A A146T MPS 30
S8426 A146P/T/V 12VAL A146V Sanger N/A
S8383 A146P/T/V N/A A146T Sanger N/A
S8397 K117N 12CYS K117N Sanger N/A
S8250 K117N N/A Q61K MPS 23
S8475 K117N N/A K117N MPS 70
S8431 A59T/E/G N/A No mutation detected MPS N/A
S8233 Q61H N/A Q61H Sanger N/A
S8377 Q61H N/A Q61H Sanger N/A
S8956 Q61H N/A Q61H MPS 42
S8494 G12V 12SER G12V MPS 37
S8546 G13D 12SER G12C MPS 33
Confirmatory testing of Idylla results using massive parallel sequencing (MPS) or Sanger Sequencing. Samples 1–13 were discordant-by-design mutations and
Samples 14–15 were mutant-mutant discordants. Samples 1–13 were not taken into account for agreement calculations
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the wild-type status of sample S8251 was only possible
after a new DNA extraction, pointing out a possible
sample contamination. One could suggest that the rea-
son for the discordant results might be the different
limit of detection of both tests, although both the ther-
ascreen KRAS RGQ PCR Kit and the CE-IVD Idylla™
KRAS Mutation Test claim to detect mutations down to
the 5% limit of detection. The LOD of the Idylla™ KRAS
Mutation Test was briefly verified and we were able to
detect previously determined KRAS mutations in 4 clin-
ical samples with a TTC content of 5-10% (Table 1). Of
note, the detection limit of G13D mutations was pub-
lished by the companies in the kit inserts to be slightly
lower for the therascreen method as compared to the
Idylla™ KRAS Mutation test (6.25% versus 5%), providing
a possible explanation for the difference in detection of
this mutation in three out of four samples. However,
analysis with Sanger sequencing as a reference approach
revealed that no KRAS mutation was present. Since these
4 samples contained a TTC of 10% or higher, we believe
that these wild-type results are not false-negative results,
but it cannot be completely excluded. Re-analysis with the
Idylla™ platform could not be performed due to insufficient
DNA material.
As mentioned before, the diagnostic yield of the
Idylla™ platform is higher due to the inclusion of muta-
tion analysis of hotspot amino acids in exon 3 and 4.
Overall, the Idylla™ platform identified 13 samples with a
mutation in exon 3 or 4, meaning that 12% (n = 13/106)
of the mutated samples would not have been detected
using the therascreen reference test, a percentage in
accordance with previous results [13]. In addition, two
samples, concordant at the mutation-mutation level, but
discordant for the type-specific mutation, were further
investigated MPS. Several studies suggested that the type
of mutation might be of importance in predicting the
response to anti-EGFR therapy or to other future therap-
ies and that it might not be sufficient to limit results to
‘mutation (not) detected’ [13, 22]. In addition, it is advis-
able to determine the specific mutation in tissue samples
whenever these results would be used in patient man-
agement to non-invasively monitor responses to treat-
ment [20]. It therefore seems to be useful at this point
to carefully determine the mutation down to the amino
acid level. In view of these considerations, we not only
searched further confirmation for the 13 mutations in
KRAS exon 3 or exon 4, but also for the two exon 2
discordant mutations at the amino acid level. (Table 5).
The Idylla™ platform identified correctly the KRAS
mutational status as compared to a reference approach
in 10 out of the 13 valid cases (Table 5). When inspect-
ing further the three discordant results (S8250, S8431
and S8546), a possible explanation might be a sample
switch or a false-positive call by the Idylla instrument.
We therefore performed additional tests and verified with
a new FFPE slide for sample S8250 the Idylla™ KRAS Mu-
tation Test result. Surprisingly, we now detected the
Q61K mutation as was confirmed with MPS and not the
K117N mutation as before. This could mean either a sam-
ple switch or sample contamination during the initial
Idylla™ KRAS test or alternatively, the presence of two
mutations in the sample with almost equal Ct. In this lat-
ter case, the Idylla™ platform would call only one muta-
tion, depending on the ΔCq value. However, the K117N
mutation could not be detected with MPS or Sanger,
meaning that a sample switch or a true false-positive call
by the instrument are the most probable reasons. The
other two discordant samples could not be verified with
the Idylla™ KRAS Mutation Test anymore due to lack of
available FFPE material. However, a sample switch is prob-
ably not the reason for the discordant result for S8431,
since no other sample in this study was positive for this
KRAS A59T/E/G mutation. This probably represents
therefore true false positive result. The third discordant
sample (S8546) generated three different mutational calls
with three different methods, suggesting that this sample
should be overall repeated or excluded from analyses.
Overall, out of the 195 valid results obtained with the
Idylla™ KRAS Mutation Test, the concordance with ther-
ascreen or another reference approach was calculated as
96.9% (n = 189/195). Overall, regardless of the confirma-
tory testing, one could conclude that the overall agree-
ment between the Idylla™ KRAS Mutation Test and the
therascreen RGQ KRAS PCR Kit is very good, namely
96.7% [95%CI: 93.0%-98.5%] and that Idylla has the
superior quality of detecting hotspot mutations in exons
3 and 4 whilst generating fewer invalid results.
The current landscape of mutation analysis is quickly
changing due to large exome and genome sequencing
projects [23]. This will possibly lead to the detection of
very rare mutations in KRAS that might be clinically
relevant, but will probably occur with a frequency that is
too low to ever firmly state their clinical relevance. The
Idylla™ platform counterbalances this by offering a quick,
on-demand system to screen for hotspot mutations with
well-known clinical relevance. On the other hand, this is
also the drawback of any available PCR based method,
since emerging mutations will not be detected with any
current KRAS Mutation PCR Test. In addition, for high-
throughput laboratories, it might be more cost-effective
to screen mCRC samples with MPS to have more output
at once, but at a slower pace. It should also be noted
that testing for NRAS mutations in KRAS wild-type
tumors is now standard of care [3]. Since almost 50% of
the tested samples will return a wild-type KRAS result,
these samples should be tested for NRAS mutations
[10, 11]. Therefore, it would be valuable in terms of
cost, labor and lab workflow efficiency to have an
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extended RAS Test that included an ‘NRAS mutation
detected’ versus ‘NRAS mutation not detected’ result
together with the KRAS result generated with the same
RAS cartridge tested. Meanwhile a separate Idylla™
NRAS/BRAF Mutation Test for CRC with a similar
turnaround time of approximately 2 h became available
which could address this unmet clinical need.
Conclusions
Overall, the Idylla™ system was able to correctly identify
the KRAS status in a high number of clinical FFPE tissue
samples, whilst being highly automated and allowing for
a rapid outcome which is needed to adequately guide
therapy in mCRC patients.
Abbreviations
12ALA: p.Gly12Ala; c.35G > C; 12ARG: p.Gly12Arg; c.34G > C;
12ASP: p.Gly12Asp; c.35G > A; 12CYS: p. Gly12Cys; c.34G > T;
12SER: p.Gly12Ser; c.34G > A; 12VAL: p. Gly12Val; c.35G > T; 13ASP: p.Gly13Asp;
c.38G > A; A146P: p.Ala146Pro; c.436G > C; A146T: p.Ala146Thr; c.436G > A;
A146V: p.Ala146Val; c.437C > T; A59E: p.Ala59Glu; c.176C > A;
A59G: p.Ala59Gly; c.176C > G; A59T: p.Ala59Thr; c.175G > A; CI: Confidence
interval; CRC: Colorectal cancer; FFPE: Formalin fixed paraffin embedded;
G12A: p.Gly12Ala; c.35G > C; G12C: p. Gly12Cys; c.34G > T; G12D: p.Gly12Asp;
c.35G > A; G12R: p.Gly12Arg; c.34G > C; G12S: p.Gly12Ser; c.34G > A; G12V: p.
Gly12Val; c.35G > T; G13D: p.Gly13Asp; c.38G > A; K117N: p.Lys117Asn;
c.351A > C; K117N: p.Lys117Asn; c.351A > T; LOD: Limit of detection;
mCRC: metastatic CRC; MPS: Massive parallel sequencing; Q61H: p.Gln61His;
c.183A > C; Q61H: p.Gln61His; c.183A > T; Q61K: p.Gln61Lys;
c.180_181delinsAA; Q61K: p.Gln61Lys; c.181C > A; Q61L: p.Gln61Leu; c.182A >
T; Q61R: p.Gln61Arg; c.182A > G; VAF: Variant allele frequency
Acknowledgements
We would like to thank all technicians from the Pathology laboratory who
participated in sectioning and staining the FFPE slides.
Funding
The Idylla™ platforms and cartridges were provided by Biocartis.
Availability of data and materials
The datasets used and/or analyzed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
C.W. performed data analysis, performed discordant testing and wrote the
manuscript. V.M., S.V.R. and R.D. are the laboratory technicians who performed
the analyses on the Idylla and RotorGeneQ instruments as well as discordant
testing. K.Z. and S.L. supported data analysis. P.P. is the guarantor of this work
and takes responsibility for the integrity of the data and the accuracy of the
data analysis. All authors read and approved the final manuscript.
Competing interests




Ethics approval and consent to participate
This study was approved by the Ethical committee of the University Hospital
Antwerp (UZA) with reference 15/3/24 and was registered at the Federal
Agency for Medicines and Health products (FAGG). All patients older than 18
hospitalized from May 2010 on at our institution consent to have residual
material tested for scientific purposes according to the Belgian legislation of




1Pathology Department, University Hospital Antwerp, Wilrijkstraat 10, 2650
Edegem, Belgium. 2Centre for Oncological Research (CORE), University of
Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Received: 9 August 2016 Accepted: 4 February 2017
References
1. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de
Velde CJ, Watanabe T. Colorectal Cancer. Nat Rev Dis Primers. 2015;1:15065.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;
65(1):5–29.
3. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 2014;25 Suppl 3:iii1–9.
4. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med.
2008;358(11):1160–74.
5. Moorcraft SY, Smyth EC, Cunningham D. The role of personalized medicine
in metastatic colorectal cancer: an evolving landscape. Ther Adv
Gastroenterol. 2013;6(5):381–95.
6. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y,
Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4
treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;
369(11):1023–34.
7. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A,
D'Haens G, Pinter T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy
as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;
360(14):1408–17.
8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T,
Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for
panitumumab efficacy in patients with metastatic colorectal cancer. J Clin
Oncol. 2008;26(10):1626–34.
9. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G,
Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of
KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus
chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a
retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.
10. NCCN. NCCN Guidelines Version 2.2016 Colon Cancer. In.; 2016.
11. NCCN. NCCN Guidelines Version 2.2016 Rectal Cancer. In.; 2016.
12. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and
panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7):1254–61.
13. Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey
JH, van Krieken JH. Prevalence of RAS mutations and individual variation
patterns among patients with metastatic colorectal cancer: A pooled analysis
of randomised controlled trials. Eur J Cancer. 2015;51(13):1704–13.
14. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C,
Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing
method for KRAS mutation detection by Pyrosequencing. J Mol Diagn.
2005;7(3):413–21.
15. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Li WQ,
Collins P, Ravetto P, et al. A multicenter blinded study to evaluate KRAS
mutation testing methodologies in the clinical setting. J Mol Diagn. 2009;
11(6):543–52.
16. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR,
Murphy KM. Comparison of Sanger sequencing, pyrosequencing, and
melting curve analysis for the detection of KRAS mutations: diagnostic and
clinical implications. J Mol Diagn. 2010;12(4):425–32.
17. Angulo B, Lopez-Rios F, Gonzalez D. A new generation of companion
diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests. Expert
Rev Mol Diagn. 2014;14(5):517–24.
18. Newcombe RG. Interval estimation for the difference between independent
proportions: comparison of eleven methods. Stat Med. 1998;17(8):873–90.
19. Altman. Practical Statistics for medical research. United States of America:
Chapman and Hall; 1991.
20. Ray K. Colorectal cancer: Liquid biopsy enables real-time monitoring of
molecular alterations in CRC. Nat Rev Gastroenterol Hepatol. 2015;12(7):372.
Weyn et al. BMC Cancer  (2017) 17:139 Page 9 of 10
21. Adema V, Torres E, Sole F, Serrano S, Bellosillo B. Paraffin treasures: do they
last forever? Biopreservation Biobanking. 2014;12(4):281–3.
22. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E.
Association of KRAS G13D tumor mutations with outcome in patients with
metastatic colorectal cancer treated with first-line chemotherapy with or
without cetuximab. J Clin Oncol. 2012;30(29):3570–7.
23. Network CGA. Comprehensive molecular characterization of human colon
and rectal cancer. Nature. 2012;487(7407):330–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Weyn et al. BMC Cancer  (2017) 17:139 Page 10 of 10
